Description
Defactinib inhibits FAK and displays anticancer activity. In ovarian cancer models, this compound decreases cell proliferation, induces apoptosis, and decreases tumor weight.
Product Unit Size | Cost | Quantity | Stock |
---|
Defactinib inhibits FAK and displays anticancer activity. In ovarian cancer models, this compound decreases cell proliferation, induces apoptosis, and decreases tumor weight.
Cas No. | 1073154-85-4 |
---|---|
Purity | ≥98% |
Formula | C20H21F3N8O3S |
Formula Wt. | 510.49 |
IUPAC Name | N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide |
Synonym | VS-6063, PF-04554878 |
Solubility | DMSO 5 mg/mL warmed (9.79 mM) Water Insoluble Ethanol Insoluble |
Appearance | White to off white powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Lee BY, Timpson P, Horvath LG, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146C:132-149. PMID: 25316657.
Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. PMID: 24062525.
Cap-dependent endonuclease inhibitor
NO donor; AR antagonist.
Camptothecin analog; topoisomerase I inhibitor,...
Rifamycin derivative, induces pore formation in...
JAK1/2 inhibitor.
Anthraquinone; IL-1β inhibitor.
Dihydropyridine, FIASMA; L-type Ca2+ channel bl...
H+/K+ ATPase and ROCK-2 inhibitor.
BRD inhibitor.
Tricyclic benzonaphthyridinone; mTORC1/2 inhibi...
Camptothecin derivative; topoisomerase I inhibi...
HDAC inhibitor.
Mineralocorticoid, aldosterone, AR antagonist, ...
Bactericidal
BTK inhibitor.
Alpha blocker and vasoactive agent.
Pesticide; demethylation inhibitor.
Neuropeptide found in insects.
Cathelicidin derivative, antimicrobial peptide,...
FIASMA, SERT and DAT inhibitor, α1-adrenergic ...